Skip to main content

Advertisement

SpringerLink
Log in

Pregnancy and rheumatic disease: “by the book” or “by the doc”

  • Review Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Pregnancy is an important condition that can affect and be affected by rheumatic disease. Overall, pregnancy is viewed as a Th2-predominant state, but several Th1-related cytokines are vital to early pregnancy. In rheumatoid arthritis for example, the majority of women improve by the beginning of the second trimester, but the majority (90%) will flare in the first 3 to 4 months postpartum. In contrast, systemic lupus erythematosus has an unpredictable course in pregnancy, leaving most rheumatologists to recommend a disease-quiescent state prior to conception. Other diseases such as scleroderma are less clear because the disease less commonly presents in the childbearing period. Many immunosuppressive medications for the rheumatic diseases are contraindicated in pregnancy because of their mechanisms of action leaving only a select few “safe” medications. Significant heterogeneity between the Food and Drug Administration (FDA) category for a medication and what a rheumatologist does in clinic leads to confusion on how a patient should be treated for active rheumatic disease both peripartum and postpartum, particularly if the patient is breastfeeding. We review the general state of pregnancy and how it is affected by prototypical rheumatic diseases including rheumatoid arthritis and systemic lupus erythematosus. In addition, we present the most commonly used disease-modifying antirheumatic drugs and immunosuppressants and explain the difference between the FDA category and clinical practice among rheumatologists. Finally, we provide some general recommendations on how to manage a rheumatic disease during pregnancy including: (a) preconception planning to ensure no teratogenic medications on board, (b) early disclosure of pregnancy to all caregivers including the rheumatologist, family physician, obstetrician, and maternal–fetal medicine specialist, and (c) planning of safe medication use for acute flare-ups and disease suppression peripartum and postpartum.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lockshin MD (2006) Treating rheumatic diseases in pregnancy: dos and don’ts. Ann Rheum Dis 65(Suppl III):iii58–iii60

    Article  PubMed  Google Scholar 

  2. Ostensen M, Villiger PM (2007) The remission of rheumatoid arthritis during pregnancy. Semin Immunopathol 29:185–191

    Article  PubMed  Google Scholar 

  3. Wegmann TG, Lin H, Guilbert L et al (1993) Bidirectional cytokine interactions in the maternal–fetal relationship: is successful pregnancy a Th2 phenomenon? Immunol Today 14:353–356

    Article  PubMed  CAS  Google Scholar 

  4. Ostensen M, Forger F, Villiger P (2006) Cytokines and pregnancy in rheumatic disease. Ann N Y Acad Sci 1069:353–363

    Article  PubMed  CAS  Google Scholar 

  5. Chaouat G, Ledee-Bataille N, Dubanchet S et al (2004) Th1/Th2 paradigm in pregnancy: paradigm lost? Int Arch Allergy Immunol 139:93–119

    Article  Google Scholar 

  6. Ashkar AA, Di Santo JP, Croy BA (2000) Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy. J Exp Med 192:25970

    Article  Google Scholar 

  7. Fukushima K, Miyamoto S, Tsukimori K et al (2005) Tumor necrosis factor and vascular endothelial growth factor induce endothelial integrin repertories, regulating endovascular differentiation and apoptosis in a human extravillous trophoblast cell line. Biol Reprod 73:172–179

    Article  PubMed  CAS  Google Scholar 

  8. Kupferminc M, Peaceman A, Aderka D (1995) Soluble tumor necrosis factor receptors in maternal plasma and second-trimester amniotic fluid. Am J Obstet Gynecol 173:900–905

    Article  PubMed  CAS  Google Scholar 

  9. Ellis J, Wennerholm UB, Bengtsson A et al (2000) Levels of dimethylarginines and cytokines in mild and severe preeclampsia. Hum Reprod 80:602–608

    Google Scholar 

  10. Bahar A, Ghalib H, Moosa R et al (2003) Maternal serum interleukin-6, interleukin-8, tumor necrosis factor-α and interferon-γ in preterm labor. Acta Obstet Gynecol Scand 82:543–549

    Article  PubMed  Google Scholar 

  11. Gerli R, Lunardi C, Vinante F et al (2001) Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol 2:72–77

    Article  Google Scholar 

  12. Correale J, Arias M, Gilmore W (1998) Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cells clone isolated from multiple sclerosis patients and normal control subjects. J Immunol 161:3365–3374

    PubMed  CAS  Google Scholar 

  13. Chrousos G, Torpy D, Gold P (1998) Interactions between the hypothalamic–pituitary–adrenal axis and the female reproductive system: clinical implications. Ann Intern Med 129:229–240

    PubMed  CAS  Google Scholar 

  14. Barrett J, Brennan P, Fiddler M et al (2000) Breastfeeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. Arthritis Rheum 43:1010–1015

    Article  PubMed  CAS  Google Scholar 

  15. Somerset D, Zheng Y, Kilby M et al (2004) Normal human pregnancy is associated with an elevation in the immune suppressive CD4+CD25+ regulatory T cell subset. Immunology 112:38–43

    Article  PubMed  CAS  Google Scholar 

  16. Brennan P (1997) HLA sharing and history of miscarriage among women with rheumatoid arthritis. Am J Hum Genet 60:738–739

    PubMed  CAS  Google Scholar 

  17. Hunt JS (2006) Stranger in a strange land. Immunol Rev 213:36–37

    Article  PubMed  CAS  Google Scholar 

  18. Crocker I, Baker P, Fletcher J (2000) Neutrophil function in pregnancy and rheumatoid arthritis. Ann Rheum Dis 59:555–564

    Article  PubMed  CAS  Google Scholar 

  19. Ostensen M (2004) New insights into sexual functioning and fertility in rheumatic diseases. Best Pract Res Clin Rheumatol 18(2):219–232

    Article  PubMed  Google Scholar 

  20. Perselin R (1977) The effect of pregnancy on rheumatoid arthritis. Bull Rheum Dis 27:922

    Google Scholar 

  21. Silman A, Kay A, Brennan P (1992) Timing of pregnancy in relation to the onset of rheumatoid arthritis. Arthritis Rheum 35:152

    Article  PubMed  CAS  Google Scholar 

  22. Ostensen M, Husby G, Romberg O (1982) Ankylosing spondylitis and motherhood. Arthritis Rheum 25:140–143

    Article  PubMed  CAS  Google Scholar 

  23. Skomsvoll J, Ostensen M, Schei B (2000) Reproduction in women reporting chronic musculoskeletal disorders. Scand J Rheumatol 29:103–107

    Article  PubMed  CAS  Google Scholar 

  24. Ostensen M, Ostensen H (1998) Ankylosing spondylitis—the female aspect. J Rheumatol 25:120–124

    PubMed  CAS  Google Scholar 

  25. Khamashta M, Hughes G (1996) Pregnancy in systemic lupus erythematosus. Curr Opin Rheumatol 8:424–442

    Article  PubMed  CAS  Google Scholar 

  26. Hardy C, Palmer BP, Morton S et al (1999) Pregnancy outcome and family size in systemic lupus erythematosus: a case-control study. Rheumatology 38:559–563

    Article  PubMed  CAS  Google Scholar 

  27. Clowse M, Madger L, Witter F et al (2006) Early risk factor for pregnancy loss in lupus. Obstet Gynecol 107:293–299

    PubMed  Google Scholar 

  28. Ruiz-Irastorza G, Lima F, Alves J et al (1996) Increased rate of lupus flare during pregnancy and the puerperium; a prospective study of 78 pregnancies. Br J Rheumatol 35:133

    Article  PubMed  CAS  Google Scholar 

  29. Kong N (2006) Pregnancy of a lupus patient—a challenge to the nephrologist. Nephrol Dial Transplant 21:268

    Article  PubMed  Google Scholar 

  30. Lockshin M (1989) Pregnancy does not cause SLE to worsen. Arthritis Rheum 32:665

    Article  PubMed  CAS  Google Scholar 

  31. McNeil H, Chesterman C, Krilis S (1991) Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 49:193

    Article  PubMed  CAS  Google Scholar 

  32. Gordon P, Khamasthta M, Rosenthal E et al (2004) Anti-52 kDa Ro, anti-60 kDa Ro and anti-La antibody profiles in neonatal lupus. J Rheumatol 31:2480–2487

    PubMed  CAS  Google Scholar 

  33. Tsakonas E, Esdaile J, Choquette D et al (1998) A long-term study on hydroxychloroquine withdrawal on exacerbations of systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 7(2):80–85

    Article  PubMed  CAS  Google Scholar 

  34. Steen V, Conte C, Day N et al (1989) Pregnancy in women with systemic sclerosis. Arthritis Rheum 32:151–157

    Article  PubMed  CAS  Google Scholar 

  35. Black C, Stevens W (1989) Scleroderma. Rheum Dis Clin North Am 15:193

    PubMed  CAS  Google Scholar 

  36. Scialli A, Buelke-Sam J, Chambers C et al (2004) Communicating risks during pregnancy: a workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugs. Birth Defects Res A Clin Mol Teratol 70:7–12

    Article  PubMed  CAS  Google Scholar 

  37. Park-Wyllie L, Mazzotta P, Pastuszak A et al (2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62:385–392

    Article  PubMed  CAS  Google Scholar 

  38. Blanford A, Murphy B (1977) In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 127:264–267

    PubMed  CAS  Google Scholar 

  39. Temprano K, Bandlamudi R, Moore T (2005) Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 35:112–121

    Article  PubMed  CAS  Google Scholar 

  40. Ostensen M (2001) Rheumatological disorders. Best Pract Res Clin Obstet Gynaecol 15(6):953–969

    Article  PubMed  CAS  Google Scholar 

  41. Motta M, Tincani A (2002) Antimalarial agents in pregnancy. Lancet 359:524–525

    Article  PubMed  Google Scholar 

  42. Canadian Rheumatology Association (2000) Canadian Consensus Conference on Hydroxychloroquine. J Rheumatol 27:2919–2920

    Google Scholar 

  43. Costedoat-Chalumeau N, Amoura Z, Dunaut P et al (2003) Safety of hydroxychloroquine in pregnant patients with connective tissue disease. Arthritis Rheum 48:3207–3214

    Article  PubMed  CAS  Google Scholar 

  44. Chambers C, Tutuncu Z, Johnson D et al (2006) Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther 8:215

    Article  PubMed  CAS  Google Scholar 

  45. Jarnerot G, Into-Malmberg M (1979) Sulphasalazine treatment during breastfeeding. Scand J Gastroentrol 14:869–871

    Article  CAS  Google Scholar 

  46. Committee on Drugs (1994) American academy of pediatrics: the transfer of drugs and other chemicals into human milk. Pediatrics 93:137–150

    Google Scholar 

  47. Armenti V, Ahlswede K, Ahlswede B et al (1994) National transplantation pregnancy registry-outcome of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 57:502

    Article  PubMed  CAS  Google Scholar 

  48. Armenti V, Radomski J, Moritz M et al (2001) Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. In: Terasaki P, Cecka JM (eds) Clinical transplants. UCLA Immunogenetics Center, Los Angeles, pp 97–105

    Google Scholar 

  49. Katz J, Keenan G, Snith D (2003) Outcome of pregnancy in patients receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Digestive Disease Week May 17–22, 2004 Orlando, FL

  50. Ostensen M, Eigenmann G (2004) Etanercept in breast milk. J Rheumatol 31:1017–1018

    PubMed  Google Scholar 

  51. Kimby E, Sverrisdottir A, Elinder G (2004) Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 72:292–295

    Article  PubMed  Google Scholar 

  52. Herold M, Schnohr S, Bittrich H (2001) Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol 19:3439

    PubMed  CAS  Google Scholar 

Download references

Disclosures

None

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Medicine, University of Alberta, 562 Heritage Medical Research Center, Edmonton, Alberta, Canada, T6G 2S2

    Stephanie O. Keeling & Anna E. Oswald

Authors
  1. Stephanie O. Keeling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna E. Oswald
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephanie O. Keeling.

Additional information

Presented as Medical Grand Rounds at the University of Alberta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keeling, S.O., Oswald, A.E. Pregnancy and rheumatic disease: “by the book” or “by the doc”. Clin Rheumatol 28, 1–9 (2009). https://doi.org/10.1007/s10067-008-1031-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-008-1031-9

Keywords

Search

Navigation